Breaking News

Tuesday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
ONCE Spark Therapeutics $77.76 0.58 (0.75%) , BCDA BioCardia … 07:20 04/17/18 04/17 07:20 04/17/18 07:20 Conference/Events	Alliance for Regenerative Medicine (ARM) to hold a conference » ARM 6th Annual Cell &… ARM 6th Annual Cell & Gene Therapy Investor Day will be held in New York on April 17. ONCE Spark Therapeutics $77.76 0.58 (0.75%) BCDA BioCardia CUR Neuralstem $1.80 0.03 (1.69%) HSGX Histogenics $2.83 -0.04 (-1.39%) VCEL Vericel $11.85 0.35 (3.04%) ADVM Adverum Biotechnologies $6.35 -0.075 (-1.17%) AGTC Applied Genetic $4.90 -0.05 (-1.01%) ADAP Adaptimmune $12.36 -0.11 (-0.88%) BRG Bluerock Residential $8.70 -0.01 (-0.11%) PFE Pfizer $36.53 0.195 (0.54%) BLUE Bluebird Bio $170.20 -3 (-1.73%) IOVA Iovance Biotherapeutics $14.75 -0.525 (-3.44%) FCSC Fibrocell Science $0.64 0.0101 (1.60%) NVS Novartis $81.19 0.145 (0.18%) BCLI BrainStorm $3.34 0.04 (1.21%) RGNX Regenxbio $38.00 3.45 (9.99%) ABEO Abeona Therapeutics $20.15 0.4 (2.03%) BOLD Audentes Therapeutics $39.84 1.96 (5.17%) FIXX Homology Medicines $20.49 0.56 (2.81%) MESO Mesoblast $6.10 0.02 (0.33%) RGRX RegeneRx CAPR Capricor Therapeutics $1.56 -0.01 (-0.64%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	17 Apr 18 Apr 19 Apr 23 Apr 24 Apr 25 Apr 03 May 08 May 17 May 21 May 23 May 05 Jun

Over a week ago
IOVA Iovance Biotherapeutics $14.45 0.6 (4.33%) 04:55 04/10/18 04/10 04:55 04/10/18 04:55 Upgrade	Iovance Biotherapeutics rating change at B. Riley FBR » Iovance Biotherapeutics… Iovance Biotherapeutics upgraded to Buy from Neutral at B. Riley FBR. B. Riley FBR analyst Madhu Kumar upgraded Iovance Biotherapeutics to Buy with an unchanged price target of $22. The recent pullback in the shares ignores the long-term potential of tumor infiltrating lymphocytes, Kumar tells investors in a research note. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
IOVA Iovance Biotherapeutics $13.85 -0.55 (-3.82%) 05:35 04/09/18 04/09 05:35 04/09/18 05:35 Hot Stocks	Iovance named as defendant in stockholder derivative complaint » Iovance Biotherapeutics… Iovance Biotherapeutics disclosed late Friday that on March 28, a purported stockholder derivative complaint was filed derivatively by plaintiff Nazeer Khaleeluddin against the company and certain of the company's current and former officers and directors in the U.S. District Court for the District of Delaware. The complaint alleges, among other things, violations of securities law, breach of fiduciary duty, aiding and abetting, waste of corporate assets, and unjust enrichment. The complaint is based on claims arising from the SEC's investigation into stock promotions and the company's April 10, 2017 settlement thereof. Iovance stated, "The Company intends to vigorously defend against the foregoing complaint. Based on the very early stage of the litigation, it is not possible to estimate the amount or range of possible loss that might result from an adverse judgment or a settlement of the matter." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
ADAP Adaptimmune $10.84 -0.21 (-1.90%) , ADRO Aduro Biotech $8.60 -0.3 (-3.37%) … 08:07 04/04/18 04/04 08:07 04/04/18 08:07 Conference/Events	William Blair to hold a conference » Annual Cancer… Annual Cancer Immunotherapy Conference will be held in New York on April 4-5. ADAP Adaptimmune $10.84 -0.21 (-1.90%) ADRO Aduro Biotech $8.60 -0.3 (-3.37%) AGEN Agenus ATRA Atara Biotherapeutics $36.25 -0.65 (-1.76%) BGNE BeiGene $165.00 -0.32 (-0.19%) BLCM Bellicum Pharmaceuticals $6.53 0.17 (2.67%) CALA Calithera Biosciences $5.85 -0.5 (-7.87%) CLLS Cellectis $38.53 7.8 (25.38%) DNA Bought by RHHBY DVAX Dynavax $18.30 -0.5 (-2.66%) FATE Fate Therapeutics $9.62 0.15 (1.58%) IDRA Idera Pharmaceuticals $1.71 0.09 (5.56%) INFI Infinity Pharmaceuticals $1.96 -0.04 (-2.00%) IOVA Iovance Biotherapeutics $14.50 -1.15 (-7.35%) LLY Eli Lilly $77.54 1.84 (2.43%) MRK Merck $54.09 0.82 (1.54%) NVS Novartis $80.12 0.53 (0.67%) PIRS Pieris Pharmaceuticals $6.55 0.07 (1.08%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	04 Apr 09 Apr 14 Apr 23 Apr 23 Apr 24 Apr 01 May 07 May 17 May 18 May 07 Jun 07 Jun 12 Jun 23 Oct 05 Apr
CCRN Cross Country Healthcare $11.33 -0.25 (-2.16%) , CBAY CymaBay $13.20 -0.33 (-2.44%) … 04:55 03/21/18 03/21 04:55 03/21/18 04:55 Conference/Events	Oppenheimer to hold a conference » 28th Annual Healthcare… 28th Annual Healthcare Conference will be held in New York on March 20-21. CCRN Cross Country Healthcare $11.33 -0.25 (-2.16%) CBAY CymaBay $13.20 -0.33 (-2.44%) GLMD Galmed $6.29 -0.28 (-4.26%) SPRO Spero Therapeutics $14.23 -0.27 (-1.86%) GBT Global Blood Therapeutics $53.00 -1.15 (-2.12%) VKTX Viking Therapeutics $5.40 0.08 (1.50%) COLL Collegium Pharmaceutical $26.40 -0.68 (-2.51%) SNSS Sunesis $3.33 -0.14 (-4.03%) VTGN VistaGen Therapeutics $1.24 -0.01 (-0.80%) APTO Aptose Biosciences $3.76 0.125 (3.44%) NLNK NewLink Genetics $7.07 0.14 (2.02%) EVOK Evoke Pharma $1.98 -0.08 (-3.88%) BPMX BioPharmX $0.31 0.0465 (17.55%) MEIP MEI Pharma $2.11 0.03 (1.44%) BLUE Bluebird Bio $189.30 -5.65 (-2.90%) IOVA Iovance Biotherapeutics $16.70 0.2 (1.21%) TNDM TNDM LMAT LeMaitre $36.90 0.33 (0.90%) PRTO Proteon Therapeutics $2.50 0.1 (4.17%) SCI Service Corp. $38.66 -0.08 (-0.21%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	21 Mar 27 Mar 29 Mar 02 Apr 04 Apr

CCRN Cross Country Healthcare $11.58 -0.41 (-3.42%) , CBAY CymaBay $13.53 -0.21 (-1.53%) … 04:55 03/20/18 03/20 04:55 03/20/18 04:55 Conference/Events	Oppenheimer to hold a conference » 28th Annual Healthcare… 28th Annual Healthcare Conference will be held in New York on March 20-21. CCRN Cross Country Healthcare $11.58 -0.41 (-3.42%) CBAY CymaBay $13.53 -0.21 (-1.53%) GLMD Galmed $6.57 -0.06 (-0.90%) SPRO Spero Therapeutics $14.50 -0.11 (-0.75%) GBT Global Blood Therapeutics $54.15 1.6 (3.04%) VKTX Viking Therapeutics $5.32 -0.06 (-1.12%) COLL Collegium Pharmaceutical $27.08 0.08 (0.30%) SNSS Sunesis $3.47 0.1 (2.97%) VTGN VistaGen Therapeutics $1.25 -0.02 (-1.57%) APTO Aptose Biosciences $3.64 -0.035 (-0.95%) NLNK NewLink Genetics $6.93 -0.31 (-4.28%) EVOK Evoke Pharma BPMX BioPharmX $0.27 -0.0044 (-1.63%) MEIP MEI Pharma $2.08 -0.01 (-0.48%) BLUE Bluebird Bio $194.95 -4.85 (-2.43%) IOVA Iovance Biotherapeutics $16.50 -0.35 (-2.08%) TNDM TNDM LMAT LeMaitre $36.57 -0.15 (-0.41%) PRTO Proteon Therapeutics $2.40 -0.05 (-2.04%) SCI Service Corp. $38.74 -0.1 (-0.26%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	20 Mar 27 Mar 29 Mar 02 Apr 04 Apr

Over a month ago
CCRN Cross Country Healthcare $11.58 -0.41 (-3.42%) , CBAY CymaBay $13.53 -0.21 (-1.53%) … 17:34 03/19/18 03/19 17:34 03/19/18 17:34 Conference/Events	Oppenheimer to hold a conference » 28th Annual Healthcare… 28th Annual Healthcare Conference will be held in New York on March 20-21. CCRN Cross Country Healthcare $11.58 -0.41 (-3.42%) CBAY CymaBay $13.53 -0.21 (-1.53%) GLMD Galmed $6.57 -0.06 (-0.90%) SPRO Spero Therapeutics $14.50 -0.11 (-0.75%) GBT Global Blood Therapeutics $54.15 1.6 (3.04%) VKTX Viking Therapeutics $5.32 -0.06 (-1.12%) COLL Collegium Pharmaceutical $27.08 0.08 (0.30%) SNSS Sunesis $3.47 0.1 (2.97%) VTGN VistaGen Therapeutics $1.25 -0.02 (-1.57%) APTO Aptose Biosciences $3.64 -0.035 (-0.95%) NLNK NewLink Genetics $6.93 -0.31 (-4.28%) EVOK Evoke Pharma BPMX BioPharmX $0.27 -0.0044 (-1.63%) MEIP MEI Pharma $2.08 -0.01 (-0.48%) BLUE Bluebird Bio $194.95 -4.85 (-2.43%) IOVA Iovance Biotherapeutics $16.50 -0.35 (-2.08%) TNDM TNDM LMAT LeMaitre $36.57 -0.15 (-0.41%) PRTO Proteon Therapeutics $2.40 -0.05 (-2.04%) SCI Service Corp. $38.74 -0.1 (-0.26%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	19 Mar 20 Mar 27 Mar 29 Mar 02 Apr 04 Apr
IOVA Iovance Biotherapeutics $19.15 0.05 (0.26%) 06:28 03/13/18 03/13 06:28 03/13/18 06:28 Recommendations	Iovance Biotherapeutics analyst commentary at B. Riley FBR » Iovance price target… Iovance price target raised to $22 from $18.50 at B. Riley FBR. B. Riley FBR analyst Madhu Kumar raised his price target for Iovance Biotherapeutics to $22 following the company's Q4 results. The analyst remains long-term positive on TIL technology in immuno-oncology, but says the absence of clinical catalysts and the stock's year-to-date share performance temper his enthusiasm near-term. He reiterates a Neutral rating on Iovance. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	13 Mar 20 Mar 04 Apr
IOVA Iovance Biotherapeutics $19.15 0.05 (0.26%) 05:30 03/13/18 03/13 05:30 03/13/18 05:30 Recommendations	Iovance Biotherapeutics analyst commentary at Jefferies » Iovance data updates in… Iovance data updates in 2018 should drive further upside, says Jefferies. Iovance Biotherapeutics last night provided an update on four ongoing clinical programs and its regulatory strategy for the melanoma program, Jefferies analyst Biren Amin writes in a post-earnings research note. Iovance continues to have an ongoing FDA dialogue and it is possible the company may be allowed to expand the current trial, the analyst adds. He sees the company's updates from Phase II melanoma, head and neck, and/or cervical studies in 2018 providing further share upside. Amin keeps a Buy rating on Iovance with a $31 price target. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	13 Mar 20 Mar 04 Apr
IOVA Iovance Biotherapeutics $19.15 0.05 (0.26%) 16:05 03/12/18 03/12 16:05 03/12/18 16:05 Earnings	Iovance Biotherapeutics reports Q4 EPS (32c), consensus (32c) » "We ended 2017… "We ended 2017 having completed significant accomplishments involving both manufacturing and clinical aspects of development of TIL as a viable commercial therapy. We developed a new manufacturing method, lasting 22 days and yielding a cryopreserved product, conducted a clinical study investigating the efficacy of this method, reported preliminary data showing responses from this generation 2 manufacturing method in late-line metastatic melanoma patients and subsequently selected this manufacturing method for all ongoing and future clinical trials for Iovance. We have also expanded our manufacturing capacity in the US, in commercial-ready suites, and built out our capacity in the EU. On the clinical front, we are currently running four studies to evaluate the potential breadth of utility of TIL therapy in multiple indications," said Maria Fardis president and CEO of Iovance Biotherapeutics. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	12 Mar 12 Mar 20 Mar 04 Apr

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial